GSK - GlaxoSmithKline plc (via Public) / GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Following in the footsteps of Eli Lilly and Regeneron, a partnership between GlaxoSmithKline and Vir Biotechnology won an emergency FDA nod for a COVID-19 antibody drug. The difference? It doesn’t have a supply deal with the U.S. government.
Scientists Donât Want to Ignore the âLab Leakâ Theory, Despite No New Evidence
Many scientists welcomed President Bidenâs call for a more rigorous investigation of a virus lab in Wuhan, China, though they said the so-called lab leak theory was still unlikely.
Security officers stood guard outside the Wuhan Institute of Virology during a visit by members of the World Health Organization team investigating the origins of the Covid-19 pandemic in February.Credit.Hector Retamal/Agence France-Presse â Getty Images
May 27, 2021Updated 12:54 p.m. ET
On the heels of President Bidenâs abrupt order to U.S. intelligence agencies to investigate the origins of the coronavirus, many scientists reacted positively, reflecting their push in recent weeks for more information about the work of a virus lab in Wuhan, China. But they cautioned against expecting an answer in the three-month time frame of the presidentâs request.
RESEARCH TRIANGLE PARK –GlaxoSmithKline has received good news on two fronts in the battle against COVID-19, reporting the launch of a Phase 3 clinical trial for a COVID-19 vaccine and also emergency authorization for use of its antibody drug from the FDA.
GSK is partnering with Sanofi on the vaccine. While other vaccines have already won approval, GSK and Sanofi are moving ahead with a global trial including some 35,000 volunteers ages 18 and over across the US as well as Asia, Africa and Latin America.
“Following encouraging interim results from the recent Phase 2 study, the companies will also begin clinical studies in the coming weeks to assess the ability of the adjuvanted recombinant-protein COVID-19 vaccine candidate to generate a strong booster response regardless of the initial vaccine platform received,” GSK said in a statement.
WA Dept. of Health says no evidence rare heart problem caused by vaccine May 26, 2021 at 5:35 pm
Dr. Stephaun Wallace, who leads the global external relations strategies COVID-19 Prevention Network at the Fred Hutchinson Cancer Research Center, receives his second injection from Dr. Tia Babu during the the Novavax Covid-19 vaccine phase 3 clinical trial at the UW Virology Research Clinic on Feb. 12, 2021 in Seattle, Washington. (Photo by Karen Ducey/Getty Images)
The Washington State Department of Health has brought the Centers for Disease Control and Prevention in to look into more than a dozen cases of a rare heart problem among Washingtonians, especially younger people, who were recently vaccinated.